Annals of Diagnostic Pathology
Volume 11, Issue 4 , Pages 252-257 , August 2007

Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion

This work was presented in part at the United States and Canadian Academy of Pathology Annual Meeting, Atlanta, Ga, February 2006.

  • Nadia Ismiil, MD, FRCPC

      Affiliations

    • Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5
    • Corresponding Author InformationCorresponding author. Tel.: +1 416 480 4278; fax: +1 416 480 4271.
    • ,
  • Golnar Rasty, MD

      Affiliations

    • Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5
    • ,
  • Zeina Ghorab, MD

      Affiliations

    • Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5
    • ,
  • Sharon Nofech-Mozes, MD

      Affiliations

    • Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5
    • ,
  • Marcus Bernardini, MD

      Affiliations

    • Division of Gynecologic Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5
    • ,
  • Ida Ackerman, MD

      Affiliations

    • Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5
    • ,
  • Gillian Thomas, MD

      Affiliations

    • Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5
    • ,
  • Allan Covens, MD

      Affiliations

    • Division of Gynecologic Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5
    • ,
  • Mahmoud A. Khalifa, MD, PhD

      Affiliations

    • Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5

References 

  1. Mariani A, Dowdy SC, Keeney GL, Long HJ, Lesnick TG, Prodratz KC. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol. 2004;95:120–126
  2. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004;35:649–662
  3. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min K-W. Expression of EGFR, Her-2/neu, p53, and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994;53:84–92
  4. Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min K-W. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994;73:370–376
  5. Stendhal U, Strang P, Wagenius G, Bergstrom R, Tribukait B. Prognostic significance of proliferation in endometrial adenocarcinomas: a multivariate analysis of clinical and flow cytometric variables. Int J Gynecol Pathol. 1991;10:271–284
  6. Pfisterer J, Kommoss F, Sauerbrei W, Rendl I, Kiechle M, Kleine W, et al. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecol Oncol. 1995;58:149–156
  7. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551–558
  8. Winkelman J, Robinson R. Adenocarcinoma of endometrium involving adenomyosis. Cancer. 1966;19:901–908
  9. Hall JB, Young RH, Nelson JH. The prognostic significance of adenomyosis in endometrial carcinoma. Gynecol Oncol. 1984;17:32–40
  10. Hayata T, Kawashima Y. Clinicopathologic study of eight cases of uterine body cancers associated with endometriosis interna (uterine adenomyosis). Am J Obstet Gynecol. 1987;156:663–666
  11. Taskin M, Lallas TA, Shevchuk M, Barber HRK. P53 expression in adenomyosis in endometrial carcinoma patients. Gynecol Oncol. 1996;62:241–246
  12. Koshiyama M, Okamoto T, Ueta M. The relationship between endometrial adenocarcinoma and coexistent adenomyosis uteri, endometriosis externa and myoma uteri. Cancer Detect Prev. 2004;28:94–98
  13. Ronnett BM, Zaino RJ, Ellenson LH, Kurman RJ. Endometrial carcinoma. In:  Kurman RJ editors. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer-Verlag; 2002;p. 501–559
  14. Nascimento AF, Hirsch MS, Cviko A, Quade BJ, Nucci MR. The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis. Mod Pathol. 2003;16:22–27
  15. Mittal KR, Barwick KW. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis. Gynecol Oncol. 1993;49:197–201
  16. Colman H, Rosenthal AH. Carcinoma developing in areas of adenomyosis. Obstet Gynecol. 1959;14:342–348
  17. Giammalvo JT, Kaplan K. The incidence of endometriosis interna in 120 cases of carcinoma of the endometrium. Am J Obstet Gynecol. 1958;75:161–165
  18. Marcus CC. Relationship of adenomyosis uteri to endometrial hyperplasia and endometrial carcinoma. Am J Obstet Gynecol. 1961;82:408–416
  19. Williams JW, Hirschowitz L. Assessment of uterine wall thickness and position of the vascular plexus in the deep myometrium: implications for the measurement of depth of myometrial invasion of endometrial carcinomas. Int J Gynecol Pathol. 2006;25:59–64
  20. Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol. 2001;14:465–471
  21. McCluggage WT, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stromal and of endometrial stromal neoplasms. Histopathology. 2001;39:273–278
  22. Sorodon M, Lein WM, Kurman RJ. CD10 immunostaining does not distinguish endometrial carcinoma invading myometrium from carcinoma involving adenomyosis. Am J Surg Pathol. 2003;27:786–789

PII: S1092-9134(06)00104-3

doi: 10.1016/j.anndiagpath.2006.08.011

Annals of Diagnostic Pathology
Volume 11, Issue 4 , Pages 252-257 , August 2007

Article Tools

* Image Usage & Resolution